tetano
Editor, Senior Moderator
Sci Rep
. 2024 May 16;14(1):11179.
doi: 10.1038/s41598-024-61906-6. Mechanistic insights into SARS-CoV-2 spike protein induction of the chemokine CXCL10
Davoud Ghazanfari[SUP] 1 [/SUP], Maria Cecilia Courreges[SUP] 2 [/SUP], Lydia E Belinski[SUP] 1 3 [/SUP], Michael J Hogrell[SUP] 1 3 [/SUP], Jacob Lloyd[SUP] 1 [/SUP], Stephen C Bergmeier[SUP] 3 4 [/SUP], Kelly D McCall[SUP] 2 3 5 6 7 8 [/SUP], Douglas J Goetz[SUP] 9 10 [/SUP]
Affiliations
During a SARS-CoV-2 infection, macrophages recognize viral components resulting in cytokine production. While this response fuels virus elimination, overexpression of cytokines can lead to severe COVID-19. Previous studies suggest that the spike protein (S) of SARS-CoV-2 can elicit cytokine production via the transcription factor NF-κB and the toll-like receptors (TLRs). In this study, we found that: (i) S and the S2 subunit induce CXCL10, a chemokine implicated in severe COVID-19, gene expression by human macrophage cells (THP-1); (ii) a glycogen synthase kinase-3 inhibitor attenuates this induction; (iii) S and S2 do not activate NF-κB but do activate the transcription factor IRF; (iv) S and S2 do not require TLR2 to elicit CXCL10 production or activate IRF; and (v) S and S2 elicit CXCL10 production by peripheral blood mononuclear cells (PBMCs). We also discovered that the cellular response, or lack thereof, to S and S2 is a function of the recombinant S and S2 used. While such a finding raises the possibility of confounding LPS contamination, we offer evidence that potential contaminating LPS does not underly induced increases in CXCL10. Combined, these results provide insights into the complex immune response to SARS-CoV-2 and suggest possible therapeutic targets for severe COVID-19.
Keywords: CXCL10 (IP-10); Glycogen Synthase Kinase-3; IRF; NF-κB; SARS-CoV-2-Spike Protein; TLR2.
. 2024 May 16;14(1):11179.
doi: 10.1038/s41598-024-61906-6. Mechanistic insights into SARS-CoV-2 spike protein induction of the chemokine CXCL10
Davoud Ghazanfari[SUP] 1 [/SUP], Maria Cecilia Courreges[SUP] 2 [/SUP], Lydia E Belinski[SUP] 1 3 [/SUP], Michael J Hogrell[SUP] 1 3 [/SUP], Jacob Lloyd[SUP] 1 [/SUP], Stephen C Bergmeier[SUP] 3 4 [/SUP], Kelly D McCall[SUP] 2 3 5 6 7 8 [/SUP], Douglas J Goetz[SUP] 9 10 [/SUP]
Affiliations
- PMID: 38750069
- DOI: 10.1038/s41598-024-61906-6
During a SARS-CoV-2 infection, macrophages recognize viral components resulting in cytokine production. While this response fuels virus elimination, overexpression of cytokines can lead to severe COVID-19. Previous studies suggest that the spike protein (S) of SARS-CoV-2 can elicit cytokine production via the transcription factor NF-κB and the toll-like receptors (TLRs). In this study, we found that: (i) S and the S2 subunit induce CXCL10, a chemokine implicated in severe COVID-19, gene expression by human macrophage cells (THP-1); (ii) a glycogen synthase kinase-3 inhibitor attenuates this induction; (iii) S and S2 do not activate NF-κB but do activate the transcription factor IRF; (iv) S and S2 do not require TLR2 to elicit CXCL10 production or activate IRF; and (v) S and S2 elicit CXCL10 production by peripheral blood mononuclear cells (PBMCs). We also discovered that the cellular response, or lack thereof, to S and S2 is a function of the recombinant S and S2 used. While such a finding raises the possibility of confounding LPS contamination, we offer evidence that potential contaminating LPS does not underly induced increases in CXCL10. Combined, these results provide insights into the complex immune response to SARS-CoV-2 and suggest possible therapeutic targets for severe COVID-19.
Keywords: CXCL10 (IP-10); Glycogen Synthase Kinase-3; IRF; NF-κB; SARS-CoV-2-Spike Protein; TLR2.